Our Speaker Meetings

Covering a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Our speaker meetings help healthcare professionals stay up-to-date with the latest scientific knowledge and advancements in clinical practice across all clinical applications. If you would like to receive more information, please contact your local sales representative.

Upcoming Meetings
Past Meetings

If you would like to receive more information, please contact your local Sales Representative.

Filter by:

Feb 9, 2024

8th NORDIC PHOTOPHERESIS MEETING

Helsinki, Finland

Feb 8, 2024

NORDIC OPERATOR DAY: THERAKOS – THE HOME OF ECP

Helsinki, Finland

Nov 23 - 24, 2023

3rd Therakos “3-Country Meeting”

Vienna, Austria

Nov 7, 2023

Extracorporeal photopheresis and chronic graft-versus-host disease

Rome, Italy

Nov 7 - 8, 2023

Operators Day

Warsaw, Poland

Oct 12 - 13, 2023

French Operator Days
This event is in French

Paris, France

Oct 3, 2023

How to improve overall survival in acute GvHD by applying ECP

Nottingham, UK

Jun 22, 2023

Overcoming the challenges in Solid Organ Transplantation with the Extracorporeal Photopheresis: What’s new?

Dubai, UAE

Jun 22, 2023

Pan-London GvHD Therapeutic Landscape in 2023 and Beyond

London, United Kingdom

Jun 8 - 9, 2023

French Operator Days
This event is in French

Paris, France

Jun 1, 2023

Nordic Photopheresis Meeting Management of CLAD

Gothenburg, Sweden

May 18, 2023

Update on the role of ECP in the management of acute & chronic GvHD

Amman, Jordan

Apr 6, 2023

CLAD and ECP: the Vienna experience

Strasbourg, France

Apr 5, 2023

CLAD and ECP: the Vienna experience

Lyon, France

Apr 4, 2023

CLAD and ECP: the Vienna experience

Nantes, France

Nov 17 - 18, 2022

Therakos Operator Meeting: ‘Sharing Best Practice’ on Extracorporeal Photopheresis
This event is in German

Hamburg, Germany

Nov 4, 2022

7th Nordic Photopheresis Meeting

Oslo, Norway

Nov 3, 2022

Nordic Operator Day: Therakos: The Home of ECP

Oslo, Norway

Oct 26, 2022

Cardiorenal meeting – ECP in management of heart and kidney transplant complications

Malmo, Sweden

Sep 30, 2022

CTCL Management in the Nordics

Virtual

Sep 22 - 24, 2022

5th Workshop on Solid Organ Transplantation (SOT) and Extracorporeal Photopheresis (ECP): Clinical Evidence and Sharing Best Practice

Monte Carlo, Monaco

Sep 15, 2022

ECP as a first-line therapy to treat aGvHD: experience from IPC Marseille
This event is in French

Virtual

Jun 27, 2022

London GvHD Therapeutic Landscape in 2022 and Beyond

London, United Kingdom

Jan 19, 2021

4^th “Advancing Immunomodulation” Meeting

Virtual Event

Nov 22, 2019

6^th Nordic Photopheresis Meeting

Stockholm, Sweden

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease.
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³.
Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOS^TM CELLEX^TMPhotopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

Our Speaker Meetings

Covering a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

8th NORDIC PHOTOPHERESIS MEETING

NORDIC OPERATOR DAY: THERAKOS – THE HOME OF ECP

3rd Therakos “3-Country Meeting”

Extracorporeal photopheresis and chronic graft-versus-host disease

Operators Day

French Operator Days This event is in French

How to improve overall survival in acute GvHD by applying ECP

Overcoming the challenges in Solid Organ Transplantation with the Extracorporeal Photopheresis: What’s new?

Pan-London GvHD Therapeutic Landscape in 2023 and Beyond

French Operator Days This event is in French

Nordic Photopheresis Meeting Management of CLAD

Update on the role of ECP in the management of acute & chronic GvHD

CLAD and ECP: the Vienna experience

CLAD and ECP: the Vienna experience

CLAD and ECP: the Vienna experience

Therakos Operator Meeting: ‘Sharing Best Practice’ on Extracorporeal Photopheresis This event is in German

7th Nordic Photopheresis Meeting

Nordic Operator Day: Therakos: The Home of ECP

Cardiorenal meeting – ECP in management of heart and kidney transplant complications

CTCL Management in the Nordics

5th Workshop on Solid Organ Transplantation (SOT) and Extracorporeal Photopheresis (ECP): Clinical Evidence and Sharing Best Practice

ECP as a first-line therapy to treat aGvHD: experience from IPC Marseille This event is in French

London GvHD Therapeutic Landscape in 2022 and Beyond

4th “Advancing Immunomodulation” Meeting

6th Nordic Photopheresis Meeting

Discover more

Centres of Excellence

Webinars

Symposia

Ask the Expert

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

Welcome to the Therakos Institute

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

French Operator Days
This event is in French

French Operator Days
This event is in French

Therakos Operator Meeting: ‘Sharing Best Practice’ on Extracorporeal Photopheresis
This event is in German

ECP as a first-line therapy to treat aGvHD: experience from IPC Marseille
This event is in French

4^th “Advancing Immunomodulation” Meeting

6^th Nordic Photopheresis Meeting

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS